Autism Aggression Sensor; Psychiatry Top Telehealth Spender; Mid-Stage Wins, Losses

A wearable biosensor paired with machine learning predicted aggression in psychiatric inpatient youths with autism 3 minutes before it happened. (JAMA Network Open)

Psychiatry had the highest share of telehealth spending, making up 33% of Medicare claims data from 2022, according to an American Medical Association report.

A federal judge said research was “cherry-picked and misrepresented” to link prenatal exposure to acetaminophen with autism and ADHD. (ABC News)

At five University of California health systems, emergency department visits for schizophrenia spectrum disorders increased 15% in the 3 months following the initial phase of the pandemic. (JAMA Network Open)

Lack of sleep can increase anxiety symptoms and dampen feelings of joy and happiness, according to a systematic review and meta-analysis in Psychological Bulletin.

MM-120, an investigational LSD therapeutic, significantly reduced symptoms of generalized anxiety disorder by week 4 in a placebo-controlled phase IIb trial when given as a single dose with no additional therapies, said Mind Medicine.

An investigative small molecule selective fatty acid amide hydrolase inhibitor flopped in a phase II trial for adults with post-traumatic stress disorder, said Jazz Pharmaceuticals. Neither dose tested met primary or secondary endpoints.

Authors of a JAMA Psychiatry viewpoint put forth the possibility that salutogenesis as a public health approach could help lessen increasing levels of mental illness and distress. The approach emphasizes health promotion, risk reduction, and the enhancement of individual and community resilience rather than just treating disease.

A Senate committee advanced legislation related to the opioid epidemic, including a bill that would change the way the FDA approves new opioids. (Endpoints News)

CNN looked at how chronic pain patients found relief with ketamine.

Bristol Myers Squibb is slated to shell out $14 billion to buy Karuna Therapeutics and its investigational schizophrenia drug KarXT. (Reuters)

Please enable JavaScript to view the

comments powered by Disqus.